mProX™ Human CD27 Stable Cell Line

Product Information

Target Family

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;KYSE150;TE3

Target Classification

CD Cell Lines

Target Research Area

Cancer Research;Infectious Research

Related Diseases

Lymphoproliferative Syndrome 2; Combined Immunodeficiency

Gene ID

Human:939

UniProt ID

Human:P26842

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD27 is a cell surface protein that has various applications in different fields. In the context of regulatory T cells (Treg), CD27 has been found to be co-expressed with the activation/memory marker HLA-DR. This subset of Treg, known as HLA-DR+CD27+ DP-Enriched Xn-Treg, exhibits enhanced antigen-specific suppressive function and has potential for the treatment of autoimmune diseases and graft rejection. CD27 has also been studied in the context of osteosarcoma, where it is implicated in influencing the prognostic and immune microenvironment of the disease. Additionally, CD27 is a therapeutic target for the treatment of various types of tumors, including lymphoma, renal cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and ovarian cancer. Antibodies targeting CD27, such as IMM40H, have been developed and shown to eliminate tumors through Fc-mediated effector functions and interrupt CD70/CD27 signaling. Furthermore, CD27 is involved in chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, where fifth-generation CAR-T cells targeting B cell maturation antigen (BCMA) and incorporating CD27 signaling have been found to enhance antitumor efficacy, proliferative capacity, and alleviate T cell exhaustion. Overall, CD27 plays a significant role in immunological responses and has potential applications in the treatment of autoimmune diseases, cancer, and infectious diseases such as COVID-19.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CD27 Stable Cell Line (S01YF-1023-PY218). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Brown (Verified Customer)

Is CD27 expression regulated at the RNA level upon antigen-specific T cell stimulation? Oct 21 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Yes, upon antigen-specific T cell stimulation, membrane expression of CD27 is regulated at the RNA level through distinct TCR/CD3-associated signaling pathways. Oct 21 2020

chat Jordan Smith (Verified Customer)

Can CD27 act as a prognostic biomarker in esophageal cancer? Sep 10 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

The degree of CD27 expression could serve as a prognostic biomarker in esophageal cancer, significantly impacting both overall survival and disease-free survival. Sep 10 2022

Published Data

Fig.1 Effect of CD27 significant on ESCC cells viability through MTS assay.

Overexpression of CD27 following a 48-hour transfection. Quantitative real-time (qRT)-PCR was used to detect the messenger RNA (mRNA) expression of CD27 in various ESCC cell lines. The MTS assay measures the impact of CD27 on the capacity for cell proliferation in KYSE150 and TE3 cells. In comparison to the control groups, there is a slight decrease (p> 0.05) in both CD27 groups.

Ref: Xiao, Fan-kai, and Lin Wang. "Comprehensive Analysis of Expression and Pathway for CD27 in Esophageal Cancer." Molecular Biotechnology (2023): 1-8.

Pubmed: 37584826

DOI: 10.1007/s12033-023-00850-8

Research Highlights

Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
In their research, a total of seven FRLncs with potential prognostic value and the ability to impact the immune microenvironment in OS were discovered. Among them, three high-risk FRLncs (APTR, AC105914.2, and AL139246.5) and four low-risk FRLncs (DSCR8, LOH12CR2, AC027307.2, and AC025048.2) were identified. Furthermore, their analysis revealed significant down-regulation of immune cell types (neutrophils, natural killer cells, plasmacytoid dendritic cells, and tumor-infiltrating lymphocytes) and immune functions (antigen-presenting cell co-stimulation, checkpoint, cytolytic activity, and T cell co-inhibition) in the high-risk group. Additionally, they pinpointed seven immune checkpoint-associated genes (CD200R1, HAVCR2, LGALS9, CD27, LAIR1, LAG3, and TNFSF4) with significant implications for OS prognosis. These findings offer a robust foundation for further exploration of OS survival and provide valuable insights for clinical decision-making in this context.
Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
Pubmed: 37858131 DOI: 10.1186/s13018-023-04286-3

Li, Song. et al. "The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling." Frontiers in oncology, 2023.
A significant level of CD70 expression has been observed in various tumor tissues, while CD27 expression is limited to Treg cells. In normal tissues, CD70 expression is low. The interaction between CD70 and CD27 has been found to promote the proliferation and survival of cancer cells and increase the levels of soluble CD27. This has been linked to unfavorable outcomes in patients with lymphoma and certain solid tumors. As a result, targeting CD70 has potential as a therapeutic approach for CD70-positive cancers such as lymphoma, RCC, NSCLC, HNSCC, and OC.
Li, Song. et al. "The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling." Frontiers in oncology, 2023.
Pubmed: 37849799 DOI: 10.3389/fonc.2023.1240061